Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Achillion Pharmaceuticals Inc (NASDAQ:ACHN)

2.83
Delayed Data
As of Dec 12
 -0.03 / -1.05%
Today’s Change
2.80
Today|||52-Week Range
5.66
-31.48%
Year-to-Date
Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma
Dec 12 / Zacks.com - Paid Partner Content
Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug
Dec 04 / Zacks.com - Paid Partner Content
Revance's Neuromodulator Injection Positive in Phase III
Dec 06 / Zacks.com - Paid Partner Content
Celldex Begins Phase I Trial on Cancer Candidate CDX-1140
Dec 01 / Zacks.com - Paid Partner Content
AstraZeneca's COPD Drug Succeeds in Label Expansion Study
Dec 05 / Zacks.com - Paid Partner Content
Merck Announces $10 Billion Buyback, Hikes Dividend by 2.1%
Nov 29 / Zacks.com - Paid Partner Content